{"organizations": [], "uuid": "49e03263dbc5ebbd89a95b91fd1fceab6c5488e8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-lysogene-had-141-million-euros-of/brief-lysogene-had-14-1-million-euros-of-cash-and-cash-equivalent-as-of-december-31-2017-idUSFWN1R80XK", "country": "US", "domain_rank": 408, "title": "BRIEF-Lysogene Had 14.1 Million Euros Of Cash And Cash Equivalent As Of December 31, 2017", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.257, "site_type": "news", "published": "2018-03-27T00:36:00.000+03:00", "replies_count": 0, "uuid": "49e03263dbc5ebbd89a95b91fd1fceab6c5488e8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-lysogene-had-141-million-euros-of/brief-lysogene-had-14-1-million-euros-of-cash-and-cash-equivalent-as-of-december-31-2017-idUSFWN1R80XK", "ord_in_thread": 0, "title": "BRIEF-Lysogene Had 14.1 Million Euros Of Cash And Cash Equivalent As Of December 31, 2017", "locations": [], "entities": {"persons": [{"name": "lysogene", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - LYSOGENE SA:\n* WELL POSITIONED TO START OUR PHASE III PIVOTAL TRIAL IN 2018 FOR LYS-SAF302\n* LYSOGENE HAD EUR 14.1 MILLION OF CASH AND CASH EQUIVALENT AS OF DECEMBER 31, 2017.\n* ALSO PLEASED WITH PROGRESS OF GM1 GANGLIOSIDOSIS PROGRAMME WITH GOAL TO START IN CLINICAL DEVELOPMENT IN 2019\n* LOSSES PER SHARE INCREASED TO EUR 1.52 IN 2017 FROM EUR 0.91 IN 2016\n* FY NET LOSS EUR 17.8 MILLION VERSUS LOSS EUR 7.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-27T00:36:00.000+03:00", "crawled": "2018-03-27T12:05:30.013+03:00", "highlightTitle": ""}